Cargando…
Reverse epitope mapping of the E2 glycoprotein in antibody associated hepatitis C virus
The humoral immune system responds to chronic hepatitis C virus (HCV) infection by producing neutralising antibodies (nAb). In this study we generated three HCV pseudoparticles in which E1E2 glycoprotein sequence was targeted by the host humoral immune system. We used patient derived virus free Fabs...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5448734/ https://www.ncbi.nlm.nih.gov/pubmed/28558001 http://dx.doi.org/10.1371/journal.pone.0175349 |
_version_ | 1783239614173020160 |
---|---|
author | Naik, Amruta S. Owsianka, Ania Palmer, Brendan A. O’Halloran, Ciaran J. Walsh, Nicole Crosbie, Orla Kenny-Walsh, Elizabeth Patel, Arvind H. Fanning, Liam J. |
author_facet | Naik, Amruta S. Owsianka, Ania Palmer, Brendan A. O’Halloran, Ciaran J. Walsh, Nicole Crosbie, Orla Kenny-Walsh, Elizabeth Patel, Arvind H. Fanning, Liam J. |
author_sort | Naik, Amruta S. |
collection | PubMed |
description | The humoral immune system responds to chronic hepatitis C virus (HCV) infection by producing neutralising antibodies (nAb). In this study we generated three HCV pseudoparticles in which E1E2 glycoprotein sequence was targeted by the host humoral immune system. We used patient derived virus free Fabs (VF-Fabs) obtained from HCV genotype 1a (n = 3), genotype 1b (n = 7) and genotype 3a (n = 1) for neutralisation of HCVpp produced in this study both individually and in combination. Based on the available anti-HCV monoclonal nAb mapping information we selected amino acid region 384–619 for conformational epitope mapping. Amongst our notable findings, we observed significant reduction in HCVpp infectivity (p<0.05) when challenged with a combination of inter genotype and subtype VF-Fabs. We also identified five binding motifs targeted by patient derived VF-Fab upon peptide mapping, of which two shared the residues with previously reported epitopes. One epitope lies within an immunodominant HVR1 and two were novel. In summary, we used a reverse epitope mapping strategy to identify preferred epitopes by the host humoral immune system. Additionally, we have combined different VF-Fabs to further reduce the HCVpp infectivity. Our data indicates that combining the antigen specificity of antibodies may be a useful strategy to reduce (in-vitro) infectivity. |
format | Online Article Text |
id | pubmed-5448734 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-54487342017-06-15 Reverse epitope mapping of the E2 glycoprotein in antibody associated hepatitis C virus Naik, Amruta S. Owsianka, Ania Palmer, Brendan A. O’Halloran, Ciaran J. Walsh, Nicole Crosbie, Orla Kenny-Walsh, Elizabeth Patel, Arvind H. Fanning, Liam J. PLoS One Research Article The humoral immune system responds to chronic hepatitis C virus (HCV) infection by producing neutralising antibodies (nAb). In this study we generated three HCV pseudoparticles in which E1E2 glycoprotein sequence was targeted by the host humoral immune system. We used patient derived virus free Fabs (VF-Fabs) obtained from HCV genotype 1a (n = 3), genotype 1b (n = 7) and genotype 3a (n = 1) for neutralisation of HCVpp produced in this study both individually and in combination. Based on the available anti-HCV monoclonal nAb mapping information we selected amino acid region 384–619 for conformational epitope mapping. Amongst our notable findings, we observed significant reduction in HCVpp infectivity (p<0.05) when challenged with a combination of inter genotype and subtype VF-Fabs. We also identified five binding motifs targeted by patient derived VF-Fab upon peptide mapping, of which two shared the residues with previously reported epitopes. One epitope lies within an immunodominant HVR1 and two were novel. In summary, we used a reverse epitope mapping strategy to identify preferred epitopes by the host humoral immune system. Additionally, we have combined different VF-Fabs to further reduce the HCVpp infectivity. Our data indicates that combining the antigen specificity of antibodies may be a useful strategy to reduce (in-vitro) infectivity. Public Library of Science 2017-05-30 /pmc/articles/PMC5448734/ /pubmed/28558001 http://dx.doi.org/10.1371/journal.pone.0175349 Text en © 2017 Naik et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Naik, Amruta S. Owsianka, Ania Palmer, Brendan A. O’Halloran, Ciaran J. Walsh, Nicole Crosbie, Orla Kenny-Walsh, Elizabeth Patel, Arvind H. Fanning, Liam J. Reverse epitope mapping of the E2 glycoprotein in antibody associated hepatitis C virus |
title | Reverse epitope mapping of the E2 glycoprotein in antibody associated hepatitis C virus |
title_full | Reverse epitope mapping of the E2 glycoprotein in antibody associated hepatitis C virus |
title_fullStr | Reverse epitope mapping of the E2 glycoprotein in antibody associated hepatitis C virus |
title_full_unstemmed | Reverse epitope mapping of the E2 glycoprotein in antibody associated hepatitis C virus |
title_short | Reverse epitope mapping of the E2 glycoprotein in antibody associated hepatitis C virus |
title_sort | reverse epitope mapping of the e2 glycoprotein in antibody associated hepatitis c virus |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5448734/ https://www.ncbi.nlm.nih.gov/pubmed/28558001 http://dx.doi.org/10.1371/journal.pone.0175349 |
work_keys_str_mv | AT naikamrutas reverseepitopemappingofthee2glycoproteininantibodyassociatedhepatitiscvirus AT owsiankaania reverseepitopemappingofthee2glycoproteininantibodyassociatedhepatitiscvirus AT palmerbrendana reverseepitopemappingofthee2glycoproteininantibodyassociatedhepatitiscvirus AT ohalloranciaranj reverseepitopemappingofthee2glycoproteininantibodyassociatedhepatitiscvirus AT walshnicole reverseepitopemappingofthee2glycoproteininantibodyassociatedhepatitiscvirus AT crosbieorla reverseepitopemappingofthee2glycoproteininantibodyassociatedhepatitiscvirus AT kennywalshelizabeth reverseepitopemappingofthee2glycoproteininantibodyassociatedhepatitiscvirus AT patelarvindh reverseepitopemappingofthee2glycoproteininantibodyassociatedhepatitiscvirus AT fanningliamj reverseepitopemappingofthee2glycoproteininantibodyassociatedhepatitiscvirus |